PE20120557A1 - Compuestos derivados de (5r)-10, 10-dimetil-7-azadispiro[3.0.4.1]decan-8-carboxamida como inhibidores del virus de la hepatitis c - Google Patents

Compuestos derivados de (5r)-10, 10-dimetil-7-azadispiro[3.0.4.1]decan-8-carboxamida como inhibidores del virus de la hepatitis c

Info

Publication number
PE20120557A1
PE20120557A1 PE2011001774A PE2011001774A PE20120557A1 PE 20120557 A1 PE20120557 A1 PE 20120557A1 PE 2011001774 A PE2011001774 A PE 2011001774A PE 2011001774 A PE2011001774 A PE 2011001774A PE 20120557 A1 PE20120557 A1 PE 20120557A1
Authority
PE
Peru
Prior art keywords
alkyl
dimethyl
decan
carboxamide
amino
Prior art date
Application number
PE2011001774A
Other languages
English (en)
Inventor
Trixi Brandl
Prakash Raman
Pascal Rigollier
Mohindra Seepersaud
Oliver Simic
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42332382&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20120557(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PE20120557A1 publication Critical patent/PE20120557A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/96—Spiro-condensed ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06139—Dipeptides with the first amino acid being heterocyclic
    • C07K5/06165—Dipeptides with the first amino acid being heterocyclic and Pro-amino acid; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0808—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0812—Tripeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/101—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1016—Tetrapeptides with the first amino acid being neutral and aromatic or cycloaliphatic

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biotechnology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Hydrogenated Pyridines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

REFERIDA A UN COMPUESTO HETEROCICLICO DE FORMULA (I), DONDE R ES ALQUILO C1-C6, ALQUENILO C2-C6 O CICLOALQUILO C3-C7-ALQUILO C0-C4; R' ES H, ALQUILO C1-C6, ENTRE OTROS; R1 Y R2 SON H, ALQUILO C1-C6, ALCOXILO C1-C6, ENTRE OTROS; R4 ES ALQUILO C1-C8, CICLOALQUILO C3-C8, ENTRE OTROS; J ES UN ENLACE O UN RESIDUO DIVALENTE DE FORMULA -NR6-CH(R5)-C(=O)-; R5 ES ALQUILO C1-C8, CICLOALQUILO C3-C8, ENTRE OTROS; R6 ES H O ALQUILO C1-C4; G ES UN GRUPO DE FORMULA -E-R7; E ES UN ENLACE, CH2, C(O), S(O)2, ENTRE OTROS; R7 ES ALQUILO C1-C6, HALOALQUILO C1-C6, ALCOXILO C1-C6, ENTRE OTROS. SON COMPUESTOS PREFERIDOS: (5R,8S)-7-[(2S)-2-{[(2S)-2-CICLOHEXIL-2-({[(2R)-1-ETIL-PIRROLIDIN-2-IL]-CARBONIL}-AMINO)-ACETIL]-AMINO}-3,3-DIMETIL-BUTANOIL]-10,10-DIMETIL-N-{(1R,2S)-1-[(PIRROLIDIN-1-IL-SULFONIL)-CARBAMOIL]-2-VINIL-CICLOPROPIL}-7-AZA-DI-ESPIRO-[3.0.4.1]-DECAN-8-CARBOXAMIDA, (5R,8S)-7-[(2S)-2-{[(2S)-2-{[(1-TERBUTIL-AZETIDIN-2-IL)-CARBONIL]-AMINO}-2-CICLOHEXIL-ACETIL]-AMINO}-3,3-DIMETIL-BUTANOIL]-10,10-DIMETIL-N-{(1R,2S)-1-[(PIRROLIDIN-1-IL-SULFONIL)-CARBAMOIL]-2-VINIL-CICLOPROPIL}-7-AZA-DI-ESPIRO-[3.0.4.1]-DECAN-8-CARBOXAMIDA, ENTRE OTROS. DICHOS COMPUESTOS SON INHIBIDORES DE PROTEASA NS3-4a DEL VIRUS DE LA HEPATITIS C
PE2011001774A 2009-04-10 2010-04-09 Compuestos derivados de (5r)-10, 10-dimetil-7-azadispiro[3.0.4.1]decan-8-carboxamida como inhibidores del virus de la hepatitis c PE20120557A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16840809P 2009-04-10 2009-04-10
US18103809P 2009-05-26 2009-05-26

Publications (1)

Publication Number Publication Date
PE20120557A1 true PE20120557A1 (es) 2012-05-23

Family

ID=42332382

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2011001774A PE20120557A1 (es) 2009-04-10 2010-04-09 Compuestos derivados de (5r)-10, 10-dimetil-7-azadispiro[3.0.4.1]decan-8-carboxamida como inhibidores del virus de la hepatitis c

Country Status (30)

Country Link
US (4) US8512690B2 (es)
EP (1) EP2417108B1 (es)
JP (1) JP5528537B2 (es)
KR (2) KR101412309B1 (es)
CN (1) CN102388023B (es)
AR (1) AR076236A1 (es)
AU (1) AU2010233472B2 (es)
BR (1) BRPI1015308A2 (es)
CA (1) CA2758146C (es)
CL (1) CL2011002494A1 (es)
CO (1) CO6440597A2 (es)
CR (1) CR20110505A (es)
CU (1) CU24046B1 (es)
EA (1) EA021554B9 (es)
EC (1) ECSP11011389A (es)
ES (1) ES2603744T3 (es)
HN (1) HN2011002635A (es)
IL (1) IL215310A (es)
MA (1) MA33155B1 (es)
MX (1) MX340733B (es)
MY (1) MY153766A (es)
NZ (1) NZ595458A (es)
PE (1) PE20120557A1 (es)
SG (1) SG174474A1 (es)
TN (1) TN2011000482A1 (es)
TW (2) TWI387591B (es)
UA (1) UA106367C2 (es)
UY (1) UY32551A (es)
WO (1) WO2010116248A1 (es)
ZA (1) ZA201106787B (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101059593B1 (ko) * 2006-04-11 2011-08-25 노파르티스 아게 Ｈｃｖ/ｈｉｖ 억제제 및 이들의 용도
EP2073831A1 (en) * 2006-10-12 2009-07-01 Novartis AG Use of modified cyclosporins
AP2011005695A0 (en) * 2008-10-15 2011-06-30 Intermune Inc Therapeutic antiviral poptides.
AR075584A1 (es) 2009-02-27 2011-04-20 Intermune Inc COMPOSICIONES TERAPEUTICAS QUE COMPRENDEN beta-D-2'-DESOXI-2'-FLUORO-2'-C-METILCITIDINA Y UN DERIVADO DE ACIDO ISOINDOL CARBOXILICO Y SUS USOS. COMPUESTO.
US8512690B2 (en) * 2009-04-10 2013-08-20 Novartis Ag Derivatised proline containing peptide compounds as protease inhibitors
BR112013008510A2 (pt) * 2010-10-08 2016-07-05 Novartis Ag vitamina e formulações de inibidores de sulfamida ns3
JP2013543500A (ja) * 2010-10-08 2013-12-05 ノバルティス アーゲー スルファミドｎｓ３阻害剤の塩類および多形
US8957203B2 (en) 2011-05-05 2015-02-17 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
LT2909205T (lt) 2012-10-19 2016-12-27 Bristol-Myers Squibb Company 9-metilpakeistieji heksadekahidrociklopropa(e)pirolo (1,2-a)(1,4)diazaciklopentadecinilkarbamato dariniai, kaip nestruktūrinės 3 (ns3) proteazės inhibitoriai, skirti hepatito c viruso infekcijų gydymui
US9643999B2 (en) 2012-11-02 2017-05-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
EP2914598B1 (en) 2012-11-02 2017-10-18 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
WO2014070964A1 (en) 2012-11-02 2014-05-08 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
WO2014070974A1 (en) 2012-11-05 2014-05-08 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
CN105164148A (zh) 2013-03-07 2015-12-16 百时美施贵宝公司 丙型肝炎病毒抑制剂
CN109152844B (zh) 2016-02-08 2022-11-22 西纳福克斯股份有限公司 用于治疗的含有磺酰胺接头的生物缀合物
US11338043B2 (en) 2016-02-08 2022-05-24 Synaffix B.V. Antibody-conjugates with improved therapeutic index for targeting HER2 tumours and method for improving therapeutic index of antibody-conjugates
US10874746B2 (en) 2016-02-08 2020-12-29 Synaffix B.V. Sulfamide linkers for use in bioconjugates
EP3728266A1 (en) 2017-12-20 2020-10-28 Novartis AG Fused tricyclic pyrazolo-dihydropyrazinyl-pyridone compounds as antivirals
CN114469952B (zh) * 2022-03-02 2023-09-19 中南大学湘雅三医院 特拉匹韦在制备malt1抑制剂、抗malt1依赖性肿瘤的药物中的应用及抗肿瘤药物

Family Cites Families (136)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE29835E (en) 1971-06-01 1978-11-14 Icn Pharmaceuticals 1,2,4-Triazole nucleosides
US3798209A (en) 1971-06-01 1974-03-19 Icn Pharmaceuticals 1,2,4-triazole nucleosides
PT72878B (en) 1980-04-24 1983-03-29 Merck & Co Inc Process for preparing mannich-base hydroxamic acid pro-drugs for the improved delivery of non-steroidal anti-inflammatory agents
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US4917888A (en) 1985-06-26 1990-04-17 Cetus Corporation Solubilization of immunotoxins for pharmaceutical compositions using polymer conjugation
JP2514950B2 (ja) 1986-03-10 1996-07-10 エフ・ホフマン―ラ ロシユ アーゲー 化学修飾蛋白質，その製造法および中間体
US5041426A (en) 1987-12-21 1991-08-20 Brigham Young University Immune system enhancing 3-β-d-ribofuranosylthiazolo[4,5-d]pyridimine nucleosides and nucleotides
DE3803225A1 (de) 1988-02-04 1989-08-17 Hoechst Ag Aminosaeureamide mit psychotroper wirkung, verfahren zu ihrer herstellung, sie enthaltende mittel und deren verwendung
GB2222770B (en) 1988-09-16 1992-07-29 Sandoz Ltd Pharmaceutical compositions containing cyclosporins
US5026687A (en) 1990-01-03 1991-06-25 The United States Of America As Represented By The Department Of Health And Human Services Treatment of human retroviral infections with 2',3'-dideoxyinosine alone and in combination with other antiviral compounds
AU660925B2 (en) 1990-04-06 1995-07-13 Genelabs Technologies, Inc. Hepatitis C virus epitopes
DK0484281T4 (da) 1990-11-02 2001-02-05 Novartis Ag Cyclosporiner
US5595732A (en) 1991-03-25 1997-01-21 Hoffmann-La Roche Inc. Polyethylene-protein conjugates
US5610054A (en) 1992-05-14 1997-03-11 Ribozyme Pharmaceuticals, Inc. Enzymatic RNA molecule targeted against Hepatitis C virus
US5382657A (en) 1992-08-26 1995-01-17 Hoffmann-La Roche Inc. Peg-interferon conjugates
ES2126658T3 (es) 1992-10-21 1999-04-01 Yoshitomi Pharmaceutical Compuesto de 2-amino-1,3-propanodiol e inmunosupresor.
DK1302468T3 (da) 1992-12-29 2009-03-02 Abbott Lab Fremgangsmåder og mellemprodukter til fremstilling af forbindelser, der inhiberer retroviral protease
DE69419244T2 (de) 1993-02-24 1999-10-14 Jui H Wang Zusammensetzungen und methoden zur anwendung von reaktiven antiviralen polymeren
AU688344B2 (en) 1993-07-19 1998-03-12 Mitsubishi-Tokyo Pharmaceuticals, Inc. Hepatitis C virus proliferation inhibitor
ES2174915T3 (es) 1993-11-10 2002-11-16 Enzon Inc Productos de conjugacion mejorados de un interferon con un polimero.
DE4415539C2 (de) 1994-05-03 1996-08-01 Osama Dr Dr Med Omer Pflanzen mit virustatischer und antiviraler Wirkung
PT778263E (pt) 1994-08-22 2002-06-28 Mitsubishi Pharma Corp Composto de benzeno e sua utilizacao farmaceutica
DE4432623A1 (de) 1994-09-14 1996-03-21 Huels Chemische Werke Ag Verfahren zur Bleichung von wäßrigen Tensidlösungen
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
JP3786447B2 (ja) 1995-03-31 2006-06-14 エーザイ株式会社 Ｃ型肝炎の予防・治療剤
US6037157A (en) 1995-06-29 2000-03-14 Abbott Laboratories Method for improving pharmacokinetics
US5908621A (en) 1995-11-02 1999-06-01 Schering Corporation Polyethylene glycol modified interferon therapy
US6054472A (en) 1996-04-23 2000-04-25 Vertex Pharmaceuticals, Incorporated Inhibitors of IMPDH enzyme
US5807876A (en) 1996-04-23 1998-09-15 Vertex Pharmaceuticals Incorporated Inhibitors of IMPDH enzyme
WO1997032018A2 (en) 1996-02-29 1997-09-04 Immusol, Inc. Hepatitis c virus ribozymes
US5633388A (en) 1996-03-29 1997-05-27 Viropharma Incorporated Compounds, compositions and methods for treatment of hepatitis C
US5830905A (en) 1996-03-29 1998-11-03 Viropharma Incorporated Compounds, compositions and methods for treatment of hepatitis C
EP0902782A1 (en) 1996-04-23 1999-03-24 Vertex Pharmaceuticals Incorporated Urea derivatives as inhibitors of impdh enzyme
US5990276A (en) 1996-05-10 1999-11-23 Schering Corporation Synthetic inhibitors of hepatitis C virus NS3 protease
US5891874A (en) 1996-06-05 1999-04-06 Eli Lilly And Company Anti-viral compound
US5837257A (en) 1996-07-09 1998-11-17 Sage R&D Use of plant extracts for treatment of HIV, HCV and HBV infections
JP3927630B2 (ja) 1996-09-27 2007-06-13 エーザイ・アール・アンド・ディー・マネジメント株式会社 ウイルス感染症の予防・治療剤
US5922757A (en) 1996-09-30 1999-07-13 The Regents Of The University Of California Treatment and prevention of hepatic disorders
PL194025B1 (pl) 1996-10-18 2007-04-30 Vertex Pharma Inhibitory proteaz serynowych, a zwłaszcza proteazy wirusa NS3 zapalenia wątroby C, kompozycja farmaceutyczna i zastosowanie inhibitorów proteaz serynowych
GB9623908D0 (en) 1996-11-18 1997-01-08 Hoffmann La Roche Amino acid derivatives
IL119833A (en) 1996-12-15 2001-01-11 Lavie David Hypericum perforatum extracts for the preparation of pharmaceutical compositions for the treatment of hepatitis
DK0966465T3 (da) 1997-03-14 2003-10-20 Vertex Pharma Inhibitorer af IMPDH-enzymer
EP1319651B1 (en) 1997-04-04 2005-06-29 Mitsubishi Pharma Corporation 2-Aminopropane-1,3-diol compound, pharmaceutical use thereof and synthetic intermediates therefor
US6004933A (en) 1997-04-25 1999-12-21 Cortech Inc. Cysteine protease inhibitors
CZ293248B6 (cs) 1997-06-30 2004-03-17 Merz Pharma Gmbh & Co. Kgaa 1-Aminocyklohexanový derivát a farmaceutická kompozice na jeho bázi
DE69827956T2 (de) 1997-08-11 2005-04-14 Boehringer Ingelheim (Canada) Ltd., Laval Peptidanaloga mit inhibitorischer wirkung auf hepatitis c
KR100954390B1 (ko) 1998-02-25 2010-04-26 에모리 유니버시티 2'-플루오로뉴클레오사이드
GB9806815D0 (en) 1998-03-30 1998-05-27 Hoffmann La Roche Amino acid derivatives
AR022061A1 (es) 1998-08-10 2002-09-04 Boehringer Ingelheim Ca Ltd Peptidos inhibidores de la hepatitis c, una composicion farmaceutica que los contiene, el uso de los mismos para preparar una composicion farmaceutica, el uso de un producto intermedio para la preparacion de estos peptidos y un procedimiento para la preparacion de un peptido analogo de los mismos.
US6323180B1 (en) 1998-08-10 2001-11-27 Boehringer Ingelheim (Canada) Ltd Hepatitis C inhibitor tri-peptides
ES2255295T3 (es) 1998-08-10 2006-06-16 Idenix (Cayman) Limited 2'-deoxi-beta-l-nucleosidos para el tratamiento de la hepatitis b.
CN1196687C (zh) 1999-03-19 2005-04-13 沃泰克斯药物股份有限公司 Impdh酶抑制剂
NZ514466A (en) 1999-04-07 2004-10-29 Pfizer Prod Inc Use of CYP2D6 inhibitors in combination therapies
CA2389745C (en) 1999-11-04 2010-03-23 Shire Biochem Inc. Method for the treatment or prevention of flaviviridae viral infection using nucleoside analogues
SK11922002A3 (sk) 2000-02-18 2003-06-03 Shire Biochem Inc. Použitie analógov nukleozidov na liečenie alebo prevenciu infekcií spôsobených flavivírusom
ES2319732T3 (es) 2000-04-13 2009-05-12 Pharmasset, Inc. Derivados de nucleosido 3'- o 2'-hidroximetilo sustituido para el tratamiento de infecciones virales.
MY164523A (en) 2000-05-23 2017-12-29 Univ Degli Studi Cagliari Methods and compositions for treating hepatitis c virus
EP1736478B1 (en) 2000-05-26 2015-07-22 IDENIX Pharmaceuticals, Inc. Methods and compositions for treating flaviviruses and pestiviruses
US6875751B2 (en) 2000-06-15 2005-04-05 Idenix Pharmaceuticals, Inc. 3′-prodrugs of 2′-deoxy-β-L-nucleosides
EP1300405B1 (en) 2000-07-13 2007-04-18 Sankyo Company, Limited Amino alcohol derivatives
US7244721B2 (en) 2000-07-21 2007-07-17 Schering Corporation Peptides as NS3-serine protease inhibitors of hepatitis C virus
EP1301527A2 (en) 2000-07-21 2003-04-16 Corvas International, Inc. Peptides as ns3-serine protease inhibitors of hepatitis c virus
CN102372764A (zh) 2000-07-21 2012-03-14 先灵公司 用作丙型肝炎病毒ns3-丝氨酸蛋白酶抑制剂的新型肽
AR029851A1 (es) * 2000-07-21 2003-07-16 Dendreon Corp Nuevos peptidos como inhibidores de ns3-serina proteasa del virus de hepatitis c
MXPA03000626A (es) 2000-07-21 2004-07-30 Schering Corp Nuevos peptidos como inhibidores de ns3-serina proteasa del virus de la hepatitis c.
WO2002018198A1 (en) 2000-08-28 2002-03-07 Roe Jae Ick Generator of two-wheeled vehicle and lighting system thereby
US20030008841A1 (en) 2000-08-30 2003-01-09 Rene Devos Anti-HCV nucleoside derivatives
SV2003000617A (es) 2000-08-31 2003-01-13 Lilly Co Eli Inhibidores de la proteasa peptidomimetica ref. x-14912m
JP2004507552A (ja) 2000-08-31 2004-03-11 メルク　エンド　カムパニー　インコーポレーテッド 免疫調節剤としてのリン酸誘導体
PT1411954E (pt) 2000-10-18 2011-03-16 Pharmasset Inc Nucleosídeos modificados para o tratamento de infecções virais e proliferação celular anormal
BR0115447A (pt) 2000-11-20 2005-10-18 Bristol Myers Squibb Co Inibidores de tripeptìdeo de hepatite c
KR20030091946A (ko) 2000-12-12 2003-12-03 쉐링 코포레이션 Ｃ형 간염 바이러스의 ｎｓ3-세린 프로테아제억제제로서의 디아릴 펩티드
WO2002048157A2 (en) 2000-12-13 2002-06-20 Bristol-Myers Squibb Pharma Company Imidazolidinones and their related derivatives as hepatitis c virus ns3 protease inhibitors
WO2002048116A2 (en) 2000-12-13 2002-06-20 Bristol-Myers Squibb Pharma Company Inhibitors of hepatitis c virus ns3 protease
AU2002232660A1 (en) 2000-12-15 2002-06-24 Pharmasset Ltd. Antiviral agents for treatment of flaviviridae infections
EP1539188B1 (en) 2001-01-22 2015-01-07 Merck Sharp & Dohme Corp. Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase
DE10102928B4 (de) 2001-01-23 2004-03-04 Infineon Technologies Ag Viterbi-Decoder und Verfahren zur Decodierung
ATE314383T1 (de) 2001-03-26 2006-01-15 Novartis Pharma Gmbh 2-amino-propanol derivate
JP2002316985A (ja) 2001-04-20 2002-10-31 Sankyo Co Ltd ベンゾチオフェン誘導体
US6963012B2 (en) 2001-09-27 2005-11-08 Kyorin Pharmaceutical Co., Ltd. Diaryl ether derivative, addition salt thereof, and immunosuppressant
DE60223699T2 (de) 2001-09-27 2008-10-30 Kyorin Pharmaceutical Co., Ltd. Diarylsulfidderivat, dessen additionssalz und immunsuppressivum
CN1300165C (zh) 2001-11-27 2007-02-14 安那迪斯药品股份有限公司 3－β－呋喃核糖基噻唑并[4,5－d]嘧啶核苷及其应用
US6973322B2 (en) 2001-12-22 2005-12-06 International Business Machines Corporation Personal travel agent using push services
EP1575964B1 (en) 2002-01-18 2009-11-11 Merck & Co., Inc. N-(benzyl)aminoalkyl carboxylate, phosphinates, phosphonates and tetrazoles as edg receptor agonists
WO2003062252A1 (en) 2002-01-18 2003-07-31 Merck & Co., Inc. Edg receptor agonists
PE20030857A1 (es) 2002-01-23 2003-10-25 Schering Corp Compuestos como inhibidores de la proteasa serina ns3 del virus de la hepatitis c
WO2004078163A2 (en) 2003-02-28 2004-09-16 Transform Pharmaceuticals, Inc. Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
MXPA04012802A (es) 2002-06-28 2005-04-19 Idenix Cayman Ltd Ester 2'-c-metil-3'-o-l-valina de ribofuranosil-citidina para el tratamiento de infecciones por flaviviridae.
CA2513213C (en) 2003-01-22 2013-07-30 Human Genome Sciences, Inc. Albumin fusion proteins
CN1798740A (zh) 2003-06-04 2006-07-05 健亚生物科技公司 含氮的杂芳基衍生物
CN101823965B (zh) 2003-06-17 2012-12-19 默沙东公司 制备(1r,2s,5s)-6,6-二甲基-3-氮杂双环[3,1,0]己烷-2-羧酸酯或其盐的方法和中间体
GB0316521D0 (en) 2003-07-15 2003-08-20 Corus Uk Ltd Improvements in or relating to damping of rail tracks
EP1646642A2 (en) 2003-07-18 2006-04-19 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases, particularly hcv ns3-ns4a protease
EP1651631A1 (en) 2003-08-01 2006-05-03 Genelabs Technologies, Inc. Bicyclic imidazol derivatives against flaviviridae
US7449447B2 (en) 2003-08-26 2008-11-11 Schering Corporation Peptidomimetic NS3-serine protease inhibitors of hepatitis C virus
AP2006003542A0 (en) 2003-09-05 2006-04-30 Anadys Pharmaceuticals Inc Administration of TLR7 ligands and prodrugs for treatment of infection by hepatitis C virus.
MY148123A (en) 2003-09-05 2013-02-28 Vertex Pharma Inhibitors of serine proteases, particularly hcv ns3-ns4a protease
JP4685775B2 (ja) 2003-09-18 2011-05-18 バーテックス ファーマシューティカルズ インコーポレイテッド セリンプロテアーゼ、とりわけｈｃｖｎｓ３−ｎｓ４ａプロテアーゼの阻害剤
NZ546663A (en) 2003-10-10 2010-01-29 Vertex Pharma Inhibitors of serine proteases, particularly HCV NS3-NS4A protease
PT1677827E (pt) 2003-10-27 2009-03-13 Vertex Pharma Associações para o tratamento do vhc
CN100509784C (zh) 2003-12-11 2009-07-08 先灵公司 丙型肝炎病毒ns3/ns4a丝氨酸蛋白酶的抑制剂
EP1711515A2 (en) 2004-02-04 2006-10-18 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases, particularly hcv ns3-ns4a protease
HUE027902T2 (en) 2004-02-09 2016-11-28 Human Genome Sciences Inc Corp Service Company Albumin fusion proteins
BRPI0508095A (pt) 2004-02-27 2007-07-17 Schering Corp compostos como inibidores de ns3 serina protease do vìrus da hepatite c
ES2346233T3 (es) 2004-02-27 2010-10-13 Schering Corporation Compuestos de azufre como inhibidores de serina proteasa ns3 del virus de la hepatitis c.
WO2005085242A1 (en) 2004-02-27 2005-09-15 Schering Corporation Novel ketoamides with cyclic p4's as inhibitors of ns3 serine protease of hepatitis c virus
ATE438622T1 (de) 2004-02-27 2009-08-15 Schering Corp 3,4-(cyclopentyl)kondensierte prolinverbindungen als inhibitoren der ns3-serinprotease des hepatitis-c-virus
US7635694B2 (en) 2004-02-27 2009-12-22 Schering Corporation Cyclobutenedione-containing compounds as inhibitors of hepatitis C virus NS3 serine protease
CA2557322A1 (en) 2004-02-27 2005-09-15 Schering Corporation Inhibitors of hepatitis c virus ns3 protease
PE20060309A1 (es) 2004-05-06 2006-04-13 Schering Corp (1r,2s,5s)-n-[(1s)-3-amino-1-(ciclobutilmetil)-2,3-dioxopropil]-3-[(2s)-2[[[(1,1-dimetiletil)amino]carbonil]amino]-3,3-dimetil-1-oxobutil]-6,6-dimetil-3-azabiciclo[3.1.o]hexan-2-carboxamida como inhibidor de la ns3/ns4a serina proteasa del virus de l
BRPI0418887A (pt) 2004-06-07 2007-10-30 Anadys Pharmaceuticals Inc nucleosìdeos de 3-beta-d-ribofuranossiltiazol[4,5-d] pirimidina e usos dos mesmos
KR20120039763A (ko) 2004-06-08 2012-04-25 버텍스 파마슈티칼스 인코포레이티드 약학 조성물
EP1773348A4 (en) 2004-07-12 2009-05-20 Idun Pharmaceuticals Inc TETRA PEPTIDE ANALOGS
MX2007002371A (es) 2004-08-27 2007-04-23 Schering Corp Compuestos de acilsulfonamida como inhibidores de la serina proteasa ns3 del virus de la hepatitis c.
CA2583494C (en) 2004-10-01 2014-01-21 Scynexis, Inc. 3-ether and 3-thioether substituted cyclosporin derivatives for the treatment and prevention of hepatitis c infection
ES2357587T3 (es) 2004-10-01 2011-04-27 Debiopharm S.A. Uso de (d-meala)3-(etval)4-ciclosporina para el tratamiento de infección por hepatitis c.
NZ554351A (en) 2004-10-01 2010-02-26 Vertex Pharma HCV NS3-NS4A protease inhibition using VX-950, also known as telaprevir
TWI437990B (zh) 2004-10-29 2014-05-21 Vertex Pharma Vx-950之醫藥用途
CN101103026A (zh) 2005-01-14 2008-01-09 健亚生物科技公司 用于治疗病毒感染的吲哚衍生物
WO2006130666A2 (en) 2005-06-02 2006-12-07 Schering Corporation Medicaments and methods combining a hcv protease inhibitor and an akr competitor
US20060281689A1 (en) 2005-06-02 2006-12-14 Schering Corporation Method for modulating activity of HCV protease through use of a novel HCV protease inhibitor to reduce duration of treatment period
WO2006130686A2 (en) 2005-06-02 2006-12-07 Schering Corporation Hcv protease inhibitors in combination with food
WO2006130553A2 (en) 2005-06-02 2006-12-07 Schering Corporation Hcv protease inhibitors
US20070021351A1 (en) 2005-06-02 2007-01-25 Schering Corporation Liver/plasma concentration ratio for dosing hepatitis C virus protease inhibitor
US7608592B2 (en) 2005-06-30 2009-10-27 Virobay, Inc. HCV inhibitors
JP2009505966A (ja) 2005-08-02 2009-02-12 バーテックス ファーマシューティカルズ インコーポレイテッド セリンプロテアーゼのインヒビター
AR055395A1 (es) 2005-08-26 2007-08-22 Vertex Pharma Compuestos inhibidores de la actividad de la serina proteasa ns3-ns4a del virus de la hepatitis c
WO2007120595A2 (en) 2006-04-11 2007-10-25 Novartis Ag Amines for the treatment of hcv
WO2007121124A2 (en) 2006-04-11 2007-10-25 Novartis Ag Hcv inhibitors comprising beta amino acids and their uses
MX2008013125A (es) 2006-04-11 2008-10-21 Novartis Ag Compuestos organicos y sus usos.
KR101059593B1 (ko) 2006-04-11 2011-08-25 노파르티스 아게 Ｈｃｖ/ｈｉｖ 억제제 및 이들의 용도
US8329159B2 (en) 2006-08-11 2012-12-11 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7888464B2 (en) 2006-11-16 2011-02-15 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
CN101868452B (zh) 2007-10-10 2014-08-06 诺华股份有限公司 螺环吡咯烷类与其对抗hcv和hiv感染的应用
US20110182850A1 (en) 2009-04-10 2011-07-28 Trixi Brandl Organic compounds and their uses
US8512690B2 (en) * 2009-04-10 2013-08-20 Novartis Ag Derivatised proline containing peptide compounds as protease inhibitors

Also Published As

Publication number Publication date
IL215310A0 (en) 2011-12-29
WO2010116248A1 (en) 2010-10-14
JP2012523404A (ja) 2012-10-04
TWI387591B (zh) 2013-03-01
EA021554B9 (ru) 2018-06-29
ECSP11011389A (es) 2011-11-30
EP2417108A1 (en) 2012-02-15
NZ595458A (en) 2013-08-30
JP5528537B2 (ja) 2014-06-25
EA021554B1 (ru) 2015-07-30
ZA201106787B (en) 2012-08-28
SG174474A1 (en) 2011-10-28
KR101412309B1 (ko) 2014-06-27
US20130022572A1 (en) 2013-01-24
CU24046B1 (es) 2014-12-26
CR20110505A (es) 2011-10-28
US8840878B2 (en) 2014-09-23
MX2011010655A (es) 2011-10-21
US8613914B2 (en) 2013-12-24
AU2010233472A1 (en) 2011-10-20
EA201101477A1 (ru) 2012-05-30
CA2758146A1 (en) 2010-10-14
KR20120004521A (ko) 2012-01-12
MX340733B (es) 2016-07-22
TW201321368A (zh) 2013-06-01
US9206232B2 (en) 2015-12-08
AU2010233472B2 (en) 2013-08-15
ES2603744T3 (es) 2017-03-01
US20100260709A1 (en) 2010-10-14
US20130034519A1 (en) 2013-02-07
TN2011000482A1 (en) 2013-03-27
US8512690B2 (en) 2013-08-20
US20140357551A1 (en) 2014-12-04
AR076236A1 (es) 2011-05-26
MY153766A (en) 2015-03-13
HN2011002635A (es) 2014-08-25
UY32551A (es) 2010-11-30
TW201040157A (en) 2010-11-16
EP2417108B1 (en) 2016-08-17
CA2758146C (en) 2017-06-06
CL2011002494A1 (es) 2012-02-24
KR20140048342A (ko) 2014-04-23
CN102388023B (zh) 2014-05-28
MA33155B1 (fr) 2012-03-01
CU20110191A7 (es) 2012-04-15
BRPI1015308A2 (pt) 2020-12-01
CN102388023A (zh) 2012-03-21
IL215310A (en) 2015-03-31
UA106367C2 (uk) 2014-08-26
CO6440597A2 (es) 2012-05-15

Similar Documents

Publication Publication Date Title
PE20120557A1 (es) Compuestos derivados de (5r)-10, 10-dimetil-7-azadispiro[3.0.4.1]decan-8-carboxamida como inhibidores del virus de la hepatitis c
DOP2019000218A (es) Inhibidores de las proteasas de serina del vhc derivados de prolinas macrocíclicas
AR072952A1 (es) Compuestos de 2-imino-3-metilpirrolopirimidinona fenilo-sustituida como inhibidores de bace-1, composiciones y su uso
AR076274A1 (es) Inhibidores del virus de la hepatitis c
AR075510A1 (es) Inhibidores del virus de la hepatitis c
PE20040951A1 (es) Derivados ciclicos como moduladores de la actividad del receptor de quimiocina
PE20121479A1 (es) Inhibidores del virus de la hepatitis c
PE20091575A1 (es) Derivados bifenilo como inhibidores del virus de la hepatitis c
PE20070115A1 (es) Derivados de [1,3,5]-triazina como inhibidores de aspartil proteasas
EA201290089A1 (ru) Химические соединения
PE20091842A1 (es) Pirrolidinonas como activadores de glucoquinasa
PE20020707A1 (es) Compuestos tripeptidicos como inhibidores de la proteasa ns3 del virus de hepatitis c
GT200600134A (es) Compuestos novedosos de derivados de aminosulfonilo
EA201101587A1 (ru) 4-циано-3-бензоиламино-n-фенилбензамиды для использования в борьбе с вредителями
EA201170241A1 (ru) Макроциклические хиноксалиновые соединения в качестве ингибиторов протеазы вгс ns3
DOP2011000298A (es) Metilo[(2s)-1-{(2s)-2-[5-(10-{2-[(2s)-1-{(2s)-2-[(metoxicarbonil) amino]-3- metilbutanoilo} pirrolidina-2-yl]-1h-imidazol-5-yl}-6-fenilindol[1,2-c][1,3] benzoxazin-3-yl)-1h-imidazol-2-yl]pirrolidina-1-yl} -3-metilo-1-oxobutan-2-yl]carbamato y uso del mismo para tratar la infección por vhc
PE20070321A1 (es) Compuestos heterociclicos como inhibidores de proteasas
ECSP099638A (es) Nuevo compuesto de adenina
PE20080677A1 (es) Inhibidores de pirrolotriazina cinaza
PE20140690A1 (es) Benzoxazepinonas fusionadas como moduladoras de canales ionicos
PE20070138A1 (es) Compuestos heterociclicos como inhibidores de aspartil proteasas
UY30437A1 (es) Quinoxalinil macroceclicos inhibidores de serina proteasa del virus de la hepatitis c
UY29016A1 (es) Analogos de dipeptidos inhibidores de la hepatitis c
UY32547A (es) Piperidinas sustituidas como antagonistas de ccr3
AR080233A1 (es) Derivados de dihidrofurano como compuestos insecticidas

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed